Why the study?
Does Tongxinluo improve diabetic peripheral neuropathy in STZ-induced diabetic rats?
Does Tongxinluo improve diabetic peripheral neuropathy in STZ-induced diabetic rats?
Tongxinluo may protect against diabetic peripheral neuropathy by inducing PGC-1α and its downstream targets involved in mitochondrial biogenesis.
Should not change clinical practice in diabetic neuropathy; hypothesis-generating for PGC-1α-targeted therapies.
Aim. To investigate the effect of Tongxinluo (Txl), a Chinese herbal compound, on diabetic peripheral neuropathy (DPN). Methods and Results. Diabetic rat model was established by peritoneal injection of streptozotocin (STZ). Txl ultrafine powder treatment for 16 weeks from the baseline significantly reversed the impairment of motor nerve conductive velocity (MNCV), mechanical hyperalgesia, and nerve structure. We further proved that Tongxinluo upregulates PGC-1α and its downstream factors including COX IV and SOD, which were involved in mitochondrial biogenesis. Conclusion. Our study indicates that the protective effect of Txl in diabetic neuropathy may be attributed to the induction of PGC-1α and its downstream targets. This finding may further illustrate the pleiotropic effect of the medicine.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: